Effects of Conventional Treatment on The Composition of The Intestinal Microbiota
Main Article Content
Abstract
Introduction: Crohn's disease is a chronic intestinal inflammation caused by genetic, immunological, microbiotic and environmental factors. The intestinal microbiota plays a crucial role in its pathogenesis, increasing the predisposition in genetically susceptible patients. Identification of changes in the gut microbiota is an important goal for predicting recurrence and remission of Crohn's disease.
Methodology: The relationship between Crohn's disease, microbiota, and postoperative recurrence was investigated through keyword search on the ResearchRabbit search engine from 2008-2023. 834 results were obtained, of which 22 relevant articles were selected for the preparation of the article.
Theoretical Framework: The intestinal microbiota plays a crucial role in the pathophysiology of inflammatory bowel diseases such as Crohn's disease. The alteration of the microbiota can increase the prevalence in genetically susceptible patients and affect the physiology of mammals. Intestinal surgery can alter the colonic microbiota in various ways, which can affect the composition and function of the microbiota. Understanding how these changes affect the colonic microbiota can help develop strategies to maintain or restore a healthy microbiota after surgery. The healthy microbiota is a protective factor for the host due to its resistance to colonization by harmful bacteria and its role in the immune system.
Conclusions: The intestinal microbiota has the potential to predict the postoperative course and recurrence of Crohn's disease
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. De Cruz P, Kang S, Wagner J, Buckley M, Sim WH,Prideaux L, et al. Association between specific mucosa-associated microbiota in Crohn's disease at the time of resection and subsequent disease recurrence: a pilot study: Microbiota in Crohn's disease. J Gastroenterol Hepatol [Internet]. 2015;30(2):268–78. Available from: http://dx.doi.org/10.1111/jgh.12694
II. Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology [Internet]. 2009;136(6):2015–31. Available from: http://dx.doi.org/10.1053/j.gastro.2009.01.072
III. Wright EK,Kamm MA, Wagner J, Teo SM, Cruz PD, Hamilton AL, et al. Microbial factors associated with postoperative Crohn's disease recurrence. J Crohns Colitis [Internet]. 2017;11(2):191–203. Available from: http://dx.doi.org/10.1093/ecco-jcc/jjw136
IV. J.M. walls,Ripollés T, Cortés X, Moreno N, Martínez MJ, Bustamante-Balén M, et al. Contrast-enhanced ultrasonography: usefulness in the assessment of postoperative recurrence of Crohn's disease. J Crohns Colitis [Internet]. 2013;7(3):192–201. Available from: http://dx.doi.org/10.1016/j.crohns.2012.03.017
V. Laffin MR, Perry T, Park H, Gillevet P, Sikaroodi M, Kaplan GG, et al. Endospore forming bacteria may be associated with maintenance of surgically-induced remission in Crohn's disease. Sci Rep [Internet]. 2018;8(1). Available from: http://dx.doi.org/10.1038/s41598-018-28071-z
VI. Hamilton AL,Kamm MA, De Cruz P, Wright EK, Feng H, Wagner J, et al. Luminal microbiota related to Crohn's disease recurrence after surgery. Gut Microbes [Internet]. 2020;11(6):1713–28. Available from: http://dx.doi.org/10.1080/19490976.2020.1778262
VII. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology [Internet]. 2014;146(6):1489–99. Available from: http://dx.doi.org/10.1053/j.gastro.2014.02.009
VIII. Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, et al. The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe [Internet]. 2014;15(3):382–92. Available from: http://dx.doi.org/10.1016/j.chom.2014.02.005
IX. Fedorak RN, Feagan BG, Hotte N, Leddin D, Dieleman LA, Petrunia DM, et al. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. Clin Gastroenterol Hepatol [Internet]. 2015;13(5):928-35.e2. Available from: http://dx.doi.org/10.1016/j.cgh.2014.10.031
X. Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 2: Surgical management and special situations. J Crohns Colitis [Internet]. 2017;11(2):135–49. Available from: http://dx.doi.org/10.1093/ecco-jcc/jjw169
XI. eleven. Nguyen GC, Loftus EV Jr, Hirano I, Falck-Ytter Y, Singh S, Sultan S, et al. American gastroenterological association institute guideline on the management of Crohn's disease after surgical resection. Gastroenterology [Internet]. 2017;152(1):271–5. Available from: http://dx.doi.org/10.1053/j.gastro.2016.10.038
XII. Buisson A.Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L. Review article: the natural history of postoperative Crohn's disease recurrence. Aliment Pharmacol Ther [Internet]. 2012;35(6):625–33. Available from: http://dx.doi.org/10.1111/j.1365-2036.2012.05002.x
XIII. Lasson A, Strid H, Ohman L, Isaksson S, Olsson M, Rydström B, et al. Fecal calprotectin one year after ileocaecal resection for Crohn's disease--a comparison with findings at ileocolonoscopy. J Crohns Colitis [Internet]. 2014;8(8):789–95. Available from: http://dx.doi.org/10.1016/j.crohns.2013.12.015
XIV. De Cruz P.Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Crohn's disease management after intestinal resection: a randomized trial. Lancet [Internet]. 2015;385(9976):1406–17. Available from: http://dx.doi.org/10.1016/S0140-6736(14)61908-5
XV. Sokol H, Pigneur B.Watterlot L, Lakhdari O, Bermúdez-Humarán LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn's disease patients. Proc Natl Acad Sci USA [Internet]. 2008;105(43):16731–6. Available from: http://dx.doi.org/10.1073/pnas.0804812105
XVI. Qiu Y, Mao R, Chen BL, He Y, Zeng ZR, Xue L, et al. Fecal calprotectin for evaluating postoperative recurrence of Crohn's disease: A meta-analysis of prospective studies. Inflamm Bowel Dis [Internet]. 2015;21(2):315–22. Available from: http://dx.doi.org/10.1097/mib.0000000000000262
XVII. Wright EK,Kamm MA, De Cruz P, Hamilton AL, Ritchie KJ, Krejany EO, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology [Internet]. 2015;148(5):938-947.e1. Available from: http://dx.doi.org/10.1053/j.gastro.2015.01.026
XVIII. Mondot S, Lepage P, Seksik P, Allez M, Tréton X, Bouhnik Y, et al. Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgery. Gut [Internet]. 2016;65(6):954–62. Available from: http://dx.doi.org/10.1136/gutjnl-2015-309184
XIX. Dey N,Soergel DAW, Repo S, Brenner SE. Association of gut microbiota with post-operative clinical course in Crohn's disease. BMC Gastroenterol [Internet]. 2013 [cited 2023 Feb 16];13(1):131. Available from: http://www.biomedcentral.com/1471-230X/13/131
XX. Battat R, Sandborn WJ. Advances in the comprehensive management of postoperative Crohn's disease. Clin Gastroenterol Hepatol [Internet]. 2022;20(7):1436–49. Available from: http://dx.doi.org/10.1016/j.cgh.2021.03.048
XXI. Frolkis AD, Dykeman J, Negrón ME, Debruyn J, Jette N, Fiest KM, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology [Internet]. 2013;145(5):996–1006. Available from: http://dx.doi.org/10.1053/j.gastro.2013.07.041
XXII. Sokol H.Brot L, Stefanescu C, Auzolle C, Barnich N, Buisson A, et al. Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's disease. Gut [Internet]. 2020;69(3):462–72. Available from: http://dx.doi.org/10.1136/gutjnl-2019-318719